Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced ...

"Combining the strengths of Phillips-Medisize and Vectura will enhance our ability to deliver a broader portfolio of inhalation combination drug devices and solutions to our pharmaceutical ...

Our lead program, molgramostim inhalation solution, is a recombinant human ... Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed ...

Our lead program, molgramostim inhalation solution, is a granulocyte-macrophage ... Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically ...

Baffles incorporated into the interior design of the nebulizer produce smaller particles and force large particles to reenter the solution ... nose versus mouth inhalation, airway obstruction ...

Mesh Nozzle Plates market Expected to Reach $57.6 Million by 2032-Allied Market Research ...

Albuterol liquid for use with a nebulizer and oral syrup are approved ... MedlinePlus. Albuterol oral inhalation. DailyMed: Label. Albuterol sulfate solution. DailyMed. Label: Albuterol sulfate syrup.

The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer ... Corporation to develop and license treprostinil ...

Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere Liquidia also obtains rights to Pharmosa’s next-generation nebulizers for use with L606 Pharmosa to receive $3.5 ...